Franklin International Growth Fund Q4 2024 Commentary
Source: SeekingAlpha
2025-01-29 05:11:00 ET
Summary
- International equities continued to struggle in the fourth quarter due to market concerns about tariff wars and potentially other punitive measures that could be levied by the second Trump administration.
- Unlike in the U.S., where moderating inflation has been accompanied by resilient GDP growth, Europe and the U.K. continue to face recession risks.
- We believe the second Trump administration introduces a wild card into recent U.S. economic and equity momentum and, with valuations well above average, leaves little room for error.
Key Takeaways
Read the full article on Seeking Alpha
For further details see:
Franklin International Growth Fund Q4 2024 Commentary
AstraZeneca PLC
NASDAQ: AZN
AZN Trading
9.5% G/L:
$93.12 Last:
2,417,086 Volume:
$93.03 Open:
AZN Latest News
March 10, 2026 08:30:00 am
AstraZeneca and Joshua Jackson partner to encourage fans to Get Body Checked Against Cancer
March 09, 2026 08:05:00 am
Koselugo approved in Canada for plexiform neurofibromas in adults with neurofibromatosis type 1
AZN Stock Data
$606,922,468,616
3,070,437,221
0.1%
781
N/A
Pharmaceuticals
Healthcare
GB
Cambridge
